IP Update, Vol. 17, No. 1 | McDermott

McDermott Will & Schulte, a global law firm

VERöFFENTLICHUNG

IP Update, Vol. 17, No. 1

January 2014

Read time: 1 min

Patents

Patents / Infringement / Burden of Proof

Unanimous Supreme Court to Federal Circuit: Burden of Proof on Infringement on Patentee, Even in Declaratory Judgment

By Paul Devinsky

A unanimous Supreme Court of the United States, in a decision authored by Justice Breyer, reversed the U.S. Court of Appeals for the Federal Circuit, holding that the patentee bears the burden of persuasion on the issue of infringement, even when the issue arises in the context of a licensee’s declaratory judgment action against the patentee. Medtronic, Inc. v. Mirowski Family Ventures, LLC, Case No. 12-1128 (Supr. Ct., Jan. 22, 2014) (Breyer, Justice).

Background

In the decision below, the Federal Circuit found that where an infringement counterclaim by a patentee is foreclosed by the continued existence of a license, the licensee seeking a declaratory judgment of non-infringement bears the burden of proof. Medtronic Inc. v. Boston Scientific Corp. et al. (IP Update, Vol. 15, No. 10).

The case involved a device known as an implantable cardioverter defibrillator. Mirowski Family Ventures (MFV), assignee of the patents, exclusively licensed the patents to Boston Scientific, which in turn sub-licensed them to Medtronic. The license agreement allowed Medtronic to challenge any assertion that newly introduced products were subject to the license via declaratory judgment. Soon afterward, Medtronic began paying royalties on a new product that Boston Scientific alleged was subject to the license and, at the same time, sought a declaratory judgment of non-infringement. Throughout the course of litigation, the parties disagreed over whether the licensee carried the burden of proving non-infringement or the licensor carried the burden of proving infringement. The district court held that the licensor carried the burden of proving infringement and ruled in favor of Medtronic because of MFV’s failure to carry its burden. MFV appealed to the Federal Circuit.

On appeal, MFV argued that because Medtronic is the party seeking relief and because MFV is foreclosed from filing a counterclaim of infringement by virtue of the license agreement between the parties, Medtronic carries the burden of proving non-infringement. Medtronic argued that the burden of proof on the issue of infringement always rests with the patentee, not with the accused infringer. The Federal Circuit agreed with MFV and held that the party seeking relief bears the burden of proving the allegations in his complaint.

The Federal Circuit explained that this burden allocation was an exception to the general rule and only applied where a license agreement prevents the licensor from asserting a counterclaim of infringement in the declaratory judgment action. The Federal Circuit further explained that because Medtronic was asking the court for relief or change of status quo, it should bear the burden of showing it was entitled to such relief.

In support of this exception, the Federal Circuit noted that the Supreme Court, in MedImmune v. Genentech (2007), held that a licensee need not breach an agreement to have standing to file a declaratory judgment action seeking a declaration of invalidity, non-infringement or unenforceability and that “in the post-MedImmune world,” the high court had thus shifted the burdens in such cases.

Amici Appellate Standing Issue Is Resolved

In its decision, the Supreme Court initially addressed a Federal Circuit jurisdictional question posed in an amicus brief filed by Tessera Technologies, a well-known licensing entity. Specifically, Tessera argued that, because MFV could not file an infringement action and the action arose in the context of a license, any dispute as to whether a product was subject to license should have been adjudicated by MFV bringing an action for damages for breach of contract.

The Supreme Court disagreed, noting that had Medtronic stopped paying royalties, MFV would have been able to terminate the license and bring an action for patent infringement. As the Court explained, such an action would arise under federal patent law because “patent law creates the cause of action. … Thus, this declaratory judgment action, which avoids that hypothetical threatened action, also ‘arises under’ federal patent law.”

The Burden of Proof Remains on the Patentee

In terms of the substantive question presented, the Supreme Court answered that when a licensee seeks declaratory judgment against a patentee, asserting that its products do not infringe the licensed patent, “the patentee bears the burden of persuasion on the issue of infringement.” Justice Breyer began his analysis with a statement of the Court’s long-held precedent that “the burden of proving infringement generally rests upon the patentee” and the operation of the Declaratory Judgment Act is only “procedural” and leaves “substantive rights unchanged.” The burden of proof, the Supreme Court explained, is a substantive aspect of a claim.

“Taken together these three legal propositions indicate that, in a licensee’s declaratory judgment action, the burden of proving infringement should remain with the patentee.”

The Supreme Court also noted “practical considerations” associated with the Federal Circuit’s burden-shifting in terms of post-litigation uncertainty about the scope of the patent, as well as “unnecessary complexity” by “compelling a licensee to prove a negative.” As the Court explained “[s]hould the declaratory judgment plaintiff fail to show noninfringement, it and others could continue to make and sell the same products, requiring the patentee to bring an infringement lawsuit and—with the burden now on the patentee—prove infringement. Thus, the declaratory judgment action would have failed to resolve the legal rights of the parties, contrary to the objective of the action.”

The Court further found the Federal Circuit rule to be inconsistent with MedImmune and with the purpose of the Declaratory Judgment Act, which was to mitigate the “dilemma” faced by a licensee as “to the choice between abandoning his [license] rights or risking” an infringement suit.

Patents / Attorneys' Fees

Federal Circuit's Last Word on Attorney Fees ─ Actual Knowledge of Baseless Claim Not Required

Addressing the proof required to show a bad faith assertion of a baseless claim to establish an exceptional patent case for attorneys’ fees. the U.S. Court of Appeals for the Federal Circuit vacated and remanded a lower court’s decision denying an award of attorneys’ fees, deciding what very well may be its last ruling on the “exceptionality” requirement for an award of attorney fees under 35 U.S.C.A. § 285 before the Supreme Court takes up the matter this term. Kilopass Tech., Inc. v. Sidense Corp., Case No. 13-1193 (Fed. Cir., Dec. 26, 2013) (O’Malley, J.) (Rader, C.J., concurring).

Defendant Sidense was granted summary judgment of non-infringement but was denied an award of attorneys’ fees by the district court. Evidence at trial tended to show that Kilopass, a direct competitor, instigated patent litigation against Sidense despite opinion of counsel that a claim for literal infringement was untenable. While there was some analysis by counsel that pursuing a claim of infringement under the doctrine of equivalence was plausible, it appeared that Kilopass’ decision to pursue litigation was uninformed by counsel’s analysis.

Kilopass subsequently filed suit against Sidense, alleging both literal infringement and infringement under the doctrine of equivalents. Despite granting summary judgment of non-infringement, the district court denied Sidense an award of attorneys’ fees, finding that Sidense had failed to prove by clear and convincing evidence that Kilopass acted in bad faith by asserting baseless infringement claims.

Sidense argued that a showing of bad faith requiring actual knowledge of a baseless claim sets too high a bar for establishing an exceptional case for an award of attorneys’ fees. The Federal Circuit clarified that bad faith only requires proof that the lack of objective foundation for the claim was either “‘known or so obvious that it should have been known’ by the party asserting the claim.”

The Federal Circuit further stressed that an analysis of § 285 focusing only on the subjective bad faith of the party asserting patent infringement, as the district court did, is inadequate to achieve justice intended under § 285. What is required is consideration of the “totality of the circumstances,” which includes objective evidence of the baselessness of the claims. The Court found that “one’s misguided belief, based on zealousness rather than reason, is simply not sufficient by itself to show that a case is not exceptional in light of objective evidence that a patentee has pressed meritless claims.” Objective evidence that a claim is baseless is therefore sufficient to create an inference of bad faith establishing an exceptional case for an award of attorneys’ fees.

Finding that the district court had only considered subjective elements of bad faith and not objective evidence that Kilopass’ claim was baseless, the Federal Circuit vacated and remanded the district court’s judgment denying fees.

In a concurring opinion, Chief Judge Rader joined the majority’s analysis and conclusion. Chief Judge Rader further endorsed the changes proposed by Sidense that objective baselessness alone should be sufficient for an award of attorneys’ fees, and that proof by a preponderance of the evidence should suffice, finding that these approaches to the fee-shifting statute are consistent with the language of the statute, the legislative intent in adopting this language, the Court’s precedent and Supreme Court precedent.

Practice Note: The Federal Circuit’s ruling in Kilopass comes before the Supreme Court addresses the standard for determining when a patent case is “exceptional” under sec. 285 and to clarify the standard appellate courts should use for reviewing such fee awards. See Octane Fitness, LLC v. Icon Health & Fitness, Inc., (IP Update, Vol. 16, No. 10), and Highmark Inc. v. Allcare Health Management Systems, Inc. (IP Update, Vol. 16, No. 10).

Patents / Infringement

An Accused Device Is “Modified” by the Installation of Software

Revisiting the wording of claims that recite a combination of hardware and software, the U.S. Court of Appeals for the Federal Circuit upheld a holding of non-infringement. Nazomi Commc’ns., Inc. v. Nokia Corp., Case No. 13-1165 (Fed. Cir., Jan. 10, 2014) (Dyk, J.) (Lourie, J., concurring).

Plaintiff patentee appealed from claim construction decision and grant of summary judgment of non-infringement. The asserted claims are apparatus claims directed to “a hardware-based [Java Virtual Machine] capable of processing stack-based instructions, that also retains the ability to run legacy (i.e., register-based) applications without utilizing the JVM.” The accused products could only perform the allegedly infringing operations after the installation of a software “technology enabling kit.” The defendants did not license or install this enabling software, and it was agreed that the accused device could not perform all of the recited steps without the software installed.

The representative claim recited “A central processing unit (CPU) capable of executing a plurality of instruction sets[,]” where one of the four instruction sets is only enabled by the absent enabling software. The plaintiff contended that the claim required only hardware that was capable of performing the claimed functionalities, and the enabling software was not required. The panel agreed with the district court’s claim construction of the district court that required a hardware and software combination capable of performing all of the allegedly infringing operations. Because the enabling software was not installed by the defendants, the panel concluded that the accused product was not capable of infringing the claims.

The panel analyzed two lines of cases applicable to the issue. The first line, relied upon by the plaintiff, involved cases where a claimed functionality was present but had to be “unlocked,” for example, by purchasing a product key, or where claims recited hardware “programmable” to perform a function. Intel Corp. v. U.S. Int’l Trade Comm’n, (programmable hardware) and Finjan v. Secure Computing, (functions unlocked with product key). According to this line of cases, even if a defendant does not unlock or program the function, the claims can still be infringed.

The second line of cases involved claims where claimed hardware is “configured to” or “programmed to” perform a set of functions. The Federal Circuit concluded that such structure claim language indicated that the recited functions must all be present in a device for infringement. Thus, unless an alleged infringer configures or programs hardware to perform a function, there is no infringement. In other words, in such a case the product must be “modified”, i.e., structurally, by adding the claimed function, whereas in the Intel and Finjan line of cases, the claimed function is already present.

The majority, analyzing the “capable of” language of the asserted patents concluded that the second line of cases applied. Installing the enabling software would modify the hardware and provide the missing function, but without the missing software, there was no infringement.

Judge Lourie concurred with the determination of the majority as to the dispositive nature of the “capable to” language, but did not join the majority in applying the “modification” rationale.

Patents / Claim Construction

Statements Describing “the Present Invention” Limit Claim Scope

In a non-precedential decision addressing the weight given to a patentee’s statements concerning “the present invention,” the U.S. Court of Appeals for the Federal Circuit affirmed the district Court’s construction, finding that a genus is limited to the specific species defined by the specification as “the present invention.” AstraZeneca AB v. Hanmi USA Inc., Case No. 13-1490 (Fed. Cir., Dec. 19, 2013) (Taranto, J.).

AstraZeneca brought suit against Hanmi, alleging a pharmaceutical drug Hanmi proposed to market in the U.S. infringed AstraZeneca’s two patents-in-suit. The patents-in-suit both relate to an omeprazole enantiomer drug used to treat acid reflux, which relates to AstraZeneca’s pharmaceutical drug popularly known as Nexium®. AstraZeneca’s Nexium has an active ingredient of the magnesium (Mg2+) salt of esomeprazole. In December 2010, Hanmi filed an application with the U.S. Food and Drug Administration (FDA) under 21 U.S.C. § 355(b)(2) seeking approval to sell a product that contains the strontium (Sr2+) salt of esomeprazole. The two patents AstraZeneca asserted against Hanmi include the claim terms “alkaline salt” and “pharmaceutically acceptable salt.”

The district court, agreeing with Hanmi’s proposed construction, construed the claim terms “alkaline salt” and “pharmaceutically acceptable salt” as limited to the “Na+, Mg2+, Li+, K+, Ca2+ or N+(R)4 salts of the single enantiomers of omeprazole.” The district court concluded that the patents-in-suit’s written description defined the invention as limited to the six disclosed salts. AstraZeneca appealed.

The Federal Circuit affirmed the district court’s ruling, holding that “the written description, by clear disclaimer, limits the claim scope to” the Na+, Mg2+, Li+, K+, Ca2+ or N+(R)4 salts of the single enantiomers of omeprazole. The Court held that “[b]y conspicuously choosing only certain members of the class, and using the language it did, AstraZeneca conveyed a clear and definitive meaning that it was disclaiming other members of the class” and the doctrine of claim differentiation could not overcome this express language in the specification.

The Court noted specific portions of the written description limited the claim term “alkaline salt.” Specifically, the Court cited the first sentence of the Detailed Description, which states “[t]he present invention refers to the new Na+, Mg2+, Li+, K+, Ca2+ or N+(R)4 salts of the single enantiomers of omeprazole.” The Court held that these statements “clearly confine the invention to the six identified cations, disclaiming anything else.” The Court noted that nothing in the written description or prosecution history expanded the scope of “alkaline salt” to include more than just these six salts. The Court, citing The Toro Co., noted “the doctrine of claim differentiation does not . . . override clear statements of scope in the specification.” The Court went on to note “[h]ere, what otherwise might be an inference from differences in claim language cannot override the unmistakable limitation of ‘alkaline salt’ set out in the written description.”

Patents / Anticipation

“Inherency Requires More Than Probabilities”

Addressing whether an essential claim limitation is inherently present in a prior art reference for purposes of an anticipation analysis, the U.S. Court of Appeals for the Federal Circuit affirmed a ruling out of the U.S. International Trade Commission (ITC), emphasizing that the burden remains on defendants to prove inherent anticipation. Motorola Mobility, LLC v. Int’l Trade Comm’n, Case No. 12-1535 (Fed. Cir., Dec. 16, 2013) (Rader, C.J.).

Microsoft filed a complaint at the ITC against Motorola for the importation and sale of mobile devices. Microsoft asserted multiple patents against Motorola, but only one was at issue in the appeal. That patent is directed to a mobile device having a personal information manager—an application that manages scheduling, communications, etc. The claimed mobile device requires “a synchronization component for synchronizing” information with a remote device.

After Motorola conceded infringement during the ITC proceeding, it was left with arguing anticipation, obviousness, and failure to establish the domestic industry requirement. The administrative law judge and the Commission rejected all three defenses. Motorola appealed.

Motorola asserted Apple’s Newton MessagePad as anticipatory prior art. A manual for the Newton system disclosed that the MessagePad may initiate synchronization with a desktop. Based on this disclosure, Motorola argued that the MessagePad must inherently include a synchronization component. To support its analysis, Motorola asserted that the claimed synchronization component merely facilitates, instead of actively manages, synchronization.

The Federal Circuit rejected Motorola’s argument as an untimely claim construction position and applied the plain and ordinary meaning of the term. The Court further found that substantial evidence supported the Commission’s holding that Motorola failed to prove inherent anticipation by clear and convincing evidence. Although it is possible that the disclosure implies the presence of a synchronization component, the fact that the MessagePad initiates synchronization does not necessitate such an implication. The Federal Circuit succinctly summarized its position, concluding that “[i]nherency requires more than probabilities or possibilities.”

The Federal Circuit also rejected Motorola’s obviousness arguments. The obviousness arguments were not based on the MessagePad, but were instead based solely on generic statements made by Microsoft’s expert. As a result, the Court found that Motorola failed to identify the scope and content of the prior art, a prerequisite to establishing obviousness. The statements from Microsoft’s expert alone were insufficient to carry Motorola’s high burden of proof.

The Federal Circuit also rejected Motorola’s argument that Microsoft failed to establish the domestic industry requirement. Motorola attacked Microsoft’s reliance on mobile devices for the technical prong of the analysis and mobile device operating systems for the economic prong. Motorola argued that these were two separate products that could not be the basis to meet the requirement. The Court rejected this argument, however, because the operating system on a mobile device is a significant part of that device. An investment directed to a significant aspect of an article is still directed to the article.

Patents / Recoverable Discovery Costs

E-Discovery Costs Related Specifically to Production Recoverable

Applying U.S. Court of Appeals for the Eleventh Circuit law and addressing whether e-discovery costs are recoverable under 28 U.S.C. § 1920(4), the U.S. Court of Appeals for the Federal Circuit reversed in part, vacated in part and remanded a district court’s decision to award defendants e-discovery costs as “the cost of making copies,” finding that, in the 11th Circuit, recovery under the statute is limited to taxation of costs directly related to documents that are actually produced and requiring that the district court perform a close fact inquiry on remand. CBT Flint Partners, LLC v. Return Path, Inc., Case No. 13-1036 (Fed. Cir., Dec. 13, 2013) (Taranto, J.) (O’Malley, J. concurring-in-part and dissenting-in-part).

CBT sued Return Path and Cisco IronPort Systems for patent infringement. After claim construction, CBT stipulated to non-infringement of the asserted claims of one asserted patent, and the district court granted summary judgment of indefiniteness on the asserted claim of the second. Defendant Cisco was awarded costs pursuant to § 1920, including $243,453.02 in fees paid to its e-discovery vendor. CBT appealed the indefiniteness ruling to the Federal Circuit, which reversed the ruling and remanded for further proceedings. The district court subsequently granted summary judgment of non-infringement. The district court awarded defendants’ renewed motions to recover costs. CBT appealed.

The Federal Circuit analyzed the scope of § 1920(4) under the law of the regional circuit, which in this case was the 11th Circuit. The 11th Circuit had not addressed § 1920(4) since the statute was amended by the Judicial Administrative and Technical Amendments Act of 2008, but earlier precedent expressed the general principle that § 1920(4) allows recovery only for costs of duplicating documents for production, not costs related to gathering documents prior to duplication. The Court found that, while the 2008 amendments contemplate electronic document production, the scope of § 1920(4) did not expand beyond costs of duplication. Accordingly, only the costs for creating the produced duplicates are recoverable, not costs for other common e-discovery activities.

The Federal Circuit used a three-stage analysis to determine whether specific e-discovery activities fall in the category of duplication:

At stage one, documents are collected and prepared for analysis. Typically, vendors copy hard drives and other media, and process them to extract individual documents, retaining the documents’ original file properties. The Court stated that such costs may be recoverable if the activities are reasonably necessary for responding to the request, e.g., if a production agreement requires specific metadata.

At stage two, documents are organized and filtered for production. This stage includes indexing, decrypting and de-duplicating files, as well as filtering, searching and reviewing for responsiveness or privilege. The result is a subset of documents for production. The Court found these activities do not constitute duplication. Rather, they are obligations outside of § 1920(4). Similarly, the Court concluded that costs for hosting documents, training or planning meetings are not recoverable.

At stage three, selected documents are copied onto media, such as hard drives or DVDs, or, in the case of source code, loaded onto secure computers for review. There was no dispute that these costs, which are directly related to copying and production, fall under the scope of § 1920(4).

The Federal Circuit remanded the case for determination of costs using the Court’s outlined approach and urged that the district court employ “common-sense judgments guided by a comparison with the paper-document analogue.”

In an opinion concurring in part and dissenting in part, Judge O’Malley dissented from the portion of the majority opinion that authorized, as “costs,” an award of the pre-duplication expenses the majority described as stage one costs. Judge O’Malley stated that she did not believe that the majority was being sufficiently mindful of the limits imposed on courts by § 1920(4). Judge O’Malley noted that the majority may have improperly expanded the statute in order to further the policy goals of shifting costs.

Patents / Publication of Patent Applications

Proceed with Caution: Navigating the Intersection Between Trade Secret and Patent Law

In a case illustrating the impact of permitting a patent application to be published, the U.S. Court of Appeals for the Federal Circuit affirmed a district court’s order granting defendant’s motion for judgment on the pleadings regarding claims for trade secret misappropriation, misrepresentation, conversion and unjust enrichment, finding that any information used by defendant was part of the public domain as a result of plaintiff’s published, and abandoned, patent application. Foster v. Pitney Bowes Corp., Case No. 13-1374, -1444 (Fed. Cir., Dec. 11, 2013) (per curiam) (nonprecedential).

Pro se appellant Frederick Foster filed a U.S. non-provisional patent application relating to a virtual mailbox system. As set forth in 35 U.S.C. 122(b), the application was published 18 months after its earliest priority date because Mr. Foster did not file a non-publication request.

After publication of the application, Mr. Foster contacted Pitney Bowes to explain his idea and pursue a partnership with Pitney Bowes. No relationship was formed, and no further communication took place. However, in 2011, Pitney Bowes launched a new website that, according to Mr. Foster, copied ideas from Mr. Foster’s application. Mr. Foster sued Pitney Bowes for, among other things, trade secret misappropriation, misrepresentation, conversion and unjust enrichment.

The district court granted judgment on the pleadings to Pitney Bowes, holding that the publication of the application undermined Mr. Foster’s claims. Mr. Foster appealed.

Regarding the trade secret claim, the Federal Circuit restated the requirements for a prima facie showing of misappropriation of trade secrets: “(1) the existence of a trade secret; (2) communication of a trade secret pursuant to a confidential relationship; (3) use of the trade secret, in violation of that confidence; and (4) harm to the plaintiff.” Additionally, a trade secret exists under Pennsylvania law only where “reasonable efforts [are made] to maintain secrecy” of the secret. Here, the Federal Circuit affirmed that no trade secret existed because Mr. Foster failed to request non-publication of the application and did not enter into a confidentiality agreement with Pitney Bowes.

The Federal Circuit also affirmed that the misrepresentation claim should fail because the publication of the application negated any reliance of Mr. Foster on alleged representations of confidentiality. Further, the district court’s finding on the conversion claim was affirmed because Mr. Foster relinquished any control he had over his idea when he permitted it to be published. Finally, the Federal Circuit affirmed that no unjust enrichment existed because the ideas in the application were already public when Mr. Foster met with Pitney Bowes and there was no evidence that Mr. Foster disclosed other ideas to Pitney Bowes not already disclosed in the application.

Patents / Obviousness

Negation of Motivation To Combine Defeats Obviousness

Addressing a finding of obviousness by the U.S. Patent and Trademark Office Board of Patent Appeals and Interferences (now the Patent Trial and Appeal Board) (Board) following inter partes reexamination, the U.S. Court of Appeals for the Federal Circuit reversed the Board’s finding, determining that the Board had failed to give proper consideration to clear teachings of both negative and positive prior art in determining if a person of ordinary skill in the art would have reasonably expected to succeed in achieving what was claimed. Institut Pasteur & Universite Pierre Et Marie Curie v. Focarino, Case No. 12-1485 (Fed. Cir., Dec. 30, 2013) (Taranto, C.J.).

Pasteur’s claims were directed to a method of targeted gene transfer into the chromosomal DNA of eukaryotic cells. The claims resulted from Pasteur’s discovery of a class of enzymes ─group I intron-encoded (GIIE) endonucleases─that were capable of cleaving chromosomal DNA at specific recognition sites. The broken DNA could be repaired by the cell’s own DNA repair mechanism known as homologous recombination so long as a template DNA with two regions homologous to either side of the break was available to the cell. Pasteur had established that by supplying a live eukaryotic cell with a GIIE endonuclease and a plasmid carrying a template DNA, it could successfully transfer a new piece of DNA from the plasmid to the cell’s chromosome.

During inter partes reexamination, Pasteur’s claims were rejected as obvious over Quirk and Bell-Pedersen prior art references that disclosed using a GIIE endonuclease to transfer DNA from plasmid to a non-chromosomal DNA in bacterial (i.e., prokaryotic) cells. In affirming this rejection, the Board relied on two other references Frey and Dujon and characterized both as disclosing cleavage of chromosomal DNA in yeast (i.e., eukaryotic) cells using a GIIE endonuclease. The Board ignored a sole negative prior-art reference teaching that targeting a GIIE endonuclease to chromosomal DNA in a living cell could be highly toxic to the cell, which might not be able to repair double-stranded breaks in the chromosome using homologous recombination. Instead, the Board relied on the interest stated by the prior art reference Old, which stated “[i]t would be a great advance if such alterations could be engineered into copies of a chosen gene in situ within the chromosomes of a living animal cell.” The Board concluded that “one of ordinary skill in the art [had] a reasonable expectation that the teachings of Quirk and Bell-Pedersen could be successfully applied to [chromosomal DNA in] yeast cells.”

The Federal Circuit reversed the Board, concluding that the Board’s decision was based on factual findings unsupported by substantial evidence. The Court stated that the key issue in this case was whether the relevant skilled artisan, after reading Quirk’s and Bell-Pedersen’s disclosure that a GIIE endonuclease can promote targeted gene transfer into non-chromosomal DNA in prokaryotic cells, would have expected that a GIIE endonuclease would successfully promote targeted gene transfer into the chromosomal DNA of eukaryotic cells, and thus had good reason to pursue that possibility.

The Federal Circuit reasoned that neither of Frey and Dujon disclosed a GIIE endonuclease cleaving yeast chromosomes while those chromosomes were in yeast cells. Frey taught cleaving extracted chromosomes. Dujon was silent about what type of DNA was cleaved in yeast. It taught GIIE when expressed in yeast could cleave DNA within the nucleus. Moreover, the Court criticized the Board for ignoring the negative prior art teachings that targeting a GIIE endonuclease to chromosomal DNA in a living cell could be highly toxic to the cell and for not offering any reason at all that a skilled artisan would have pursued a method that was toxic to cells. Instead, the Federal Circuit reasoned that such a negative teaching counts significantly against finding a motivation to take the claimed steps with a reasonable expectation of success.

The Federal Circuit stated that the prior art presented in this case, at best, confirmed the great potential payoff of a method that produced a particular result. The desire for that payoff could motivate pursuit of the method, but “knowledge of the goal does not render its achievement obvious,” and obviousness generally requires that a skilled artisan have reasonably expected success in achieving that goal, which was not present here. Thus, the Court reversed the Board’s decision in favor of Pasteur.

Practice Note: The Court had previously established that the reasonable-expectation-of-success test requires a skilled artisan to be “motivated to do more than merely to vary all parameters or try each of numerous possible choices until one possibly arrived at a successful result, where the prior art gave either no indication of which parameters were critical or no direction as to which of many possible choices is likely to be successful [In re O’Farrell].” This decision further shows that negative references that negate motivation can be used in favor of non-obviousness via the reasonable-expectation-of-success test.

Patents / Prosecution History Estoppel

Be Careful What You Draw: Prosecution History Estoppel Applies to Design Patents

Addressing for the first time the applicability of prosecution history estoppel in design patent cases, the U.S. Court of Appeals for the Federal Circuit reversed the lower court, holding that while prosecution history estoppel does apply to design patents, the accused infringing design must be within the scope of the subject matter surrendered during prosecution. Pacific Coast Marine v. Malibu Boats, LLC, Case No. 13-1199 (Fed. Cir., Jan. 8, 2014) (Dyk, J.).

Pacific Coast Marine (PCM) filed a design patent application for an “ornamental design of a marine windshield with a frame, a tapered corner post with vent holes and without said vent holes, and with a hatch and without said hatch, as shown and described.” The drawings depicted embodiments with four, two, or zero vent holes. The examiner issued a restriction requirement, finding patentably distinct groups of designs. PCM elected a design with four vent holes and removed claim language and any figures referring to other embodiments. The application issued into a patent with the claim “[t]he ornamental design for a marine windshield, as shown and described” and was assigned to PCM.

PCM sued Malibu Boats (Malibu) alleging infringement of the patent by a boat windshield manufactured and sold by Malibu, which contained three trapezoidal holes in the corners of the windshield. The district court, recognizing that the accused design had one fewer hole than the PCM patented design, concluded that the accused design was within the territory surrendered by PCM during prosecution and granted Malibu’s summary judgment motion of non-infringement based on prosecution history estoppel. PCM appealed.

The Court held that although the claimed scope of design patents is defined by drawings rather than language, the principles of prosecution history estoppel applies to design patents as well as utility patents. The Court relied on a three-part inquiry to determine whether prosecution history estoppel bars infringement: “(1) whether there was a surrender; (2) whether it was for reasons of patentability; and (3) whether the accused design is within the scope of the surrender.”

First, to determine whether surrender existed, the Court looked at the drawings, which provide the scope and description of the invention. PCM amended the claim in response to a restriction requirement by cancelling all figures except the four-hole embodiment and removed reference to alternate configurations from the text. “By cancelling figures showing corner posts with two holes and no holes, the applicant surrendered such designs and conceded that the claim was limited to what the remaining figure showed—a windshield with four holes in the corner post—and colorable imitations thereof.” Thus, the applicant surrendered subject matter by narrowing the scope of the original application.

Second, the surrender must be for reasons of patentability PCM argued that surrenders to avoid prior art are the only surrenders within the prosecution history estoppel doctrine. The Court disagreed, citing to Festo: “[t]he rationale behind prosecution history estoppel does not cease simply because the narrowing amendment, submitted to secure a patent, was for some purpose other than avoiding prior art.” Festo. The Court held that even though the surrender was made in response to a restriction requirement and not a patentability issue, claim scope was indeed surrendered in order to secure the patent as contemplated by Festo.

Finally, the Court addressed whether the accused design was within the scope of the surrender. The district court found that a three-hole design was within the territory of the original claim (which included a two-hole design) and the patented claim (directed to a four-hole design). Malibu argued that PCM abandoned the range between two- and four-holed embodiments. However, the Court explained that the “range concept does not work in the context of design patents where ranges are not claimed, but rather individual designs. Claiming different designs does not necessarily suggest that the territory between those designs is also claimed.” For this reason, the Court held that the principles of prosecution history estoppel did not bar PCM’s infringement claim.

Practice Note: While claiming multiple embodiments in design patents may result in a stronger patent, there is a risk of receiving a restriction requirement from the examiner. Filing divisional applications for the unelected embodiments is one option for avoiding prosecution history estoppel.

Cert Alert

Is “Insolubly Ambiguous” the Correct Standard to Determine Compliance with Sec 112?

By Paul Devinsky

The U.S. Supreme Court granted certiorari on a petition challenging the U.S. Court of Appeals for the Federal Circuit’s standard for determining when a patent claim is indefinite under 35 U.S.C. §112, ¶ 2. See IP Update, Vol. 16, No. 5. Under the Federal Circuit’s 2005 ruling in Datamize LLC v. Plumtree Software Inc., a claim is invalid only if it cannot be construed or is “insolubly ambiguous.” Nautilus, Inc. v. Biosig Instruments, Inc. (Case. No. 13-369, cert granted Jan. 10, 2014).

The petition asks two questions:

  • Does the Federal Circuit’s acceptance of ambiguous patent claims with multiple reasonable interpretations—so long as the ambiguity is not “insoluble” by a court—defeat the statutory requirement of particular and distinct patent claiming?
  • Does the presumption of validity dilute the requirement of particular and distinct patent claiming?

Supreme Court to Consider Inducement in the Context of Divided Infringement

The Supreme Court granted cert on the question of whether infringement can be found when more than one party performs steps of a patented method. Limelight Networks Inc. v. Akamai Techs. Inc., (Case No. 12-786, review granted Jan. 10, 2014).

The question presented is:

Whether the Federal Circuit erred in holding that a defendant may be held liable for inducing patent infringement under 35 U.S.C. §271(b) even though no one has committed direct infringement under §271(a).

The U.S. Court of Appeals for the Federal Circuit, sitting en banc, divided 6-5 in overturning its own precedent, concluding that a patent owner claiming induced infringement under Section 271(b) no longer had to establish as a predicate that a single entity was liable for direct infringement under Section 271(a). Rather, the Federal Circuit explained that the holder of a method claim can prevail if it can show that the accused inducer performs some steps of the claim and induces an end user to perform the other steps. Akamai Technologies v. Limelight Networks.

In its brief, the U.S. government called for a reversal of the Federal Circuit’s new inducement standard, which it characterized as “a significant expansion of the scope of inducement liability… that is not justified under a proper understanding of section 271.” The government urged that if a “statutory gap” exists in the infringement statute, it is up to Congress to fill it. See IP Update, Vol. 16, No. 12.

Is Internet Streaming a “Public Performance” of a TV Program?

The U.S. Supreme Court granted cert on a petition challenging the U.S. Court of Appeals for the Second Circuit’s determination that Aereo Inc.’s internet streaming service did not infringe the copyright in the program content based on the legal conclusion that transmission of the programming to individual Internet subscribers does not constitute a “public performance” under the Copyright Act. American Broadcasting Cos. v. Aereo, Inc. (Case No. 13-461, cert granted Jan 10, 2014). See IP Update, Vol. 16, No. 5 for discussion of the 2d Circuit decision.

The broadcaster’s petition argued that the 2d Circuit’s interpretation of the public performance right constitutes “nonsensical reasoning [that] cannot be reconciled with the plain text of the Copyright Act or Congress’ manifest intent to include retransmission services within the scope of the public-performance right.”

Aereo did not oppose the petition, noting that while there was not yet a circuit split on the issue, in view of the large number of law suits it faced, such a split was likely and it agreed that the high court should consider the issue.

The petition identified the question presented as:

Whether a company “publicly performs” a copyrighted television program when it retransmits a broadcast of that program to thousands of paid subscribers over the internet.

Can a Lanham Act Claim Be Subject to FDA Preemption?

The U.S. Supreme Court granted a petition for certiorari challenging the U.S. Court of Appeals for the Ninth Circuit’s determination that a Lanham Act false advertising claim was barred by the Federal Food, Drug, and Cosmetics Act. Pom Wonderful LLC v. The Coca-Cola Co., (Case No. 12-761, cert granted Jan 10, 2014).

Pom Wonderful challenged Coca-Cola’s labeling of its product as “Pomegranate Blueberry” when the beverage contained just 0.3 percent pomegranate juice and 0.2 percent blueberry juice. More than 99 percent of the content was apple and grape juice. The 9th Circuit affirmed summary judgment for Coca-Cola, concluding that the FDA’s rules regarding false and misleading food and beverage labels limited claims under the Lanham Act. According to the 9th Circuit, the existence of these FDA regulations preempted false advertising claims based on food and beverage labels.

The U.S. government filed a brief taking the position that the 9th Circuit had misconstrued the scope of the preemptive effect of the FDCA but that the Ninth Circuit result was correct in this instance because Coca-Cola’s product was labeled in a manner specifically allowed by the FDCA.

The Supreme Court nevertheless decided to grant review.

Patents / ITC / Domestic Industry

ITC Now Requires Satisfaction of the “Technical Prong” for Licensing-Based Domestic Industries

Reversing course from longstanding practice, the U.S. International Trade Commission (ITC or Commission) has held that proof of “articles protected by the patent” (i.e., a technical prong) is now required for satisfaction of the domestic industry requirement (DI requirement), even where the DI allegation is based on licensing investments under 19 U.S.C. § 1337(a)(3)(C). Certain Computers and Computer Peripheral Devices, and Components Thereof, and Products Containing the Same, Inv. No. 337-TA-841 (Comm’n Op., public version Jan. 9, 2014) (Comm’r Aronoff dissenting)

The domestic industry requirement of § 337 has traditionally required satisfaction of both the “economic prong” and the “technical prong.” However, the Commission’s practice had previously been not to require a complainant to demonstrate a technical prong in the form of articles practicing the asserted patents for a licensing-based domestic industry. The Commission based this approach primarily upon the legislative history adding § 337(a)(3)(C) to the domestic industry requirement in 1988. In the 841 investigation, the administrative law judge (ALJ) relied upon this practice to find that the complainant Technology Properties Limited (TPL) satisfied the domestic industry requirement even though it did not prove the existence of any articles protected by the patent.

In its review of the ALJ’s Initial Determination, the Commission reconsidered its prior practice in light of certain recent U.S. Court of Appeals for the Federal Circuit decisions. In particular, the Commission interpreted the Federal Circuit’s recent holdings in InterDigital v. ITC (IP Update, Vol. 16, No. 1) and Microsoft v. ITC (IP Update, Vol. 16, No. 10) as requiring articles protected by the patent even for licensing-based domestic industries. In InterDigital, the court held that “just as the ‘plant or equipment’ referred to in subparagraph (A) [of § 337(a)(3)] must exist with respect to articles protected by the patent, such as by producing protected goods, the research and development or licensing activities referred to in subparagraph (C) must also exist with respect to articles protected by the patent, such as by licensing protected products.” The Commission found that that “the only plausible interpretation of the opinion is to impose an ‘articles’ requirement for subparagraph (C) domestic industries, including licensing-based domestic industries.” The Commission further stated that the InterDigital opinion should not be misconstrued to suggest that this requirement may be satisfied by merely pointing to the articles that are accused of infringement. Additionally, in Microsoft, the Federal Circuit held that §§ 337(a)(2),(3) “unmistakably requires that the domestic company’s substantial investments relate to actual ‘articles protected by the patent.’” The Commission indicated that “[w]hile Microsoft was decided in the context of engineering and research and development, we do not interpret the opinion to provide a special, and more lenient, test for licensing-based industries.”

Although proof of articles protected by the patent was required, the Commission refused to impose a “production-driven” requirement on licensing-based domestic industries. The Commission noted that it has only previously “expressed a preference—but not a requirement —for production-driven licensing, giving more weight to evidence of such licensing.” Applying this revised interpretation of the statutory requirement, the Commission found that TPL failed to satisfy the requirement because it did not prove that any of its own or its licensees’ articles practiced the asserted patents.

In dissent, Commissioner Aranoff relied upon the legislative history and prior Commission precedent to argue that satisfaction of articles protected by the patent should not be required for licensing domestic industries. Commissioner Aranoff expressed the view that the better reading of the InterDigital opinions is that they do not bind the Commission to requiring an articles requirement for licensing-based domestic industries under § 337(a)(3)(C) because that would be consistent with the Federal Circuit’s ultimate decision to uphold the Commission’s determination of the existence of a domestic industry where InterDigital did not allege, and the Commission never found, any specific articles that practiced the asserted patents.

Patents / IPR

The PTAB’s User Manual for Amending Claims

In what is only the second final written decision of an inter partes review (IPR), the United States Patent and Trademark Office Patent Trial and Appeals Board (Board) cancelled all claims under review, finding for petitioner and delineating the requirements the Board will expect patent owners to meet when seeking to amend claims in future IPR proceedings. Idle Free Systems, Inc. v. Bergstrom, Inc., Case IPR2012-00027 (PTAB, Jan. 7, 2014).

The petitioner, Idle Free Systems, filed a petition for IPR of a patent owned by Bergstrom, which Bergstrom had asserted against Idle Free in a district court action. The invention relates to an automobile air conditioning system that operates at different speeds based on available power sources, which can include the running engine of the vehicle, its battery and other power sources such as an onboard generator or an electrical outlet. The invention allegedly automatically alters operation of the air conditioning system at different “capacities” or speeds, depending on available power source, thereby maximizing battery life.

The Board agreed with Idle Free on seven of nine grounds of review, and the IPR was instituted for all claims in the patent. At oral conference, Bergstrom conceded that claims 1-4, 8, 10, and 17-19 were unpatentable on the grounds instituted for those claims. On its own, and without having conferred with the Board beforehand as is required by 37 C.F.R. § 42.121(a), Bergstrom filed a Motion to Amend claims 17-19. The Board dismissed the Motion to Amend as not complying with § 42.121(a). However, the Board provided Bergstrom with another opportunity to amend its claims and advised Bergstrom as to which requirements were not met by the initial Motion to Amend. Bergstrom’s second Motion to Amend, however, was still deficient.

In the final decision, the Board explained the fatal shortcomings in Bergstrom’s second Motion to Amend. Because Bergstrom, as the patent owner, had the burden to show entitlement to its requested relief, that is, entry of the proposed substitute claims, it was required to demonstrate patentability of the proposed substitute claims, by a preponderance of the evidence, over the prior art in general and not just the prior art references applied by the petitioner against the original patent claims. Bergstrom remedied certain deficiencies of its initial motion to amend, including showing support in the specification for the newly proposed claims, as well as showing that limitations of the proposed claims were not taught or suggested by the Petitioner’s identified prior art. However, Bergstrom’s second motion was nevertheless inadequate because it did not set forth what Bergstrom knew about the level of ordinary skill in the art and what was previously known in the art, regarding each feature it relied upon for establishing patentability of its proposed substitute claims. The Board explained that for each such feature, if Bergstrom was not the first to have invented or developed it, Bergstrom should have revealed in its motion if such technical features existed in other contexts, and, if so, how they worked. If Bergstrom believed that it was the first to invent or develop a feature, it should have stated so in its motion. Unfortunately, Bergstrom did neither.

Practice Note: Petitioners may want to attack proposed claim amendments by emphasizing how proposed claims are not adequately framed with respect to the state of the art and skill set available to a person of ordinary skill in the art. Patent owners desiring to amend many claims in a patent may want to consider following the Board’s advice from its first decision dismissing Bergstrom’s initial attempt to amend its claims and file for either a reissue application or a request for ex parte reexamination of a patent, relying on the Board’s institution of an IPR as raising the required substantial new question of unpatentability.

IPR’s Are Time Barred by Pre-AIA Litigation

Addressing the one-year time-bar relating to petitions for inter partes review (IPR) of patents asserted in litigation, the U.S. Patent and Trademark Office Patent Trial and Appeals Board (Board) denied four IPR petitions as being time-barred, confirming that litigation commenced prior to the effective date of the America Invents Act (AIA) will trigger the one-year bar. Samsung Electronics Co. Ltd. v. Fractus, S.A., Case Nos. IPR2014-00008, -00011, -00012, and -00013 (PTAB, Jan. 2, 2014).

Petitioner, Samsung Electronics, filed petitions for IPR of four related patents. Samsung’s IPR petitions came five days before filing requests for ex parte review of the same patents and after previously having filed multiple requests for inter partes reexamination for each patent over a span of three years. The patents related to antennas with specific shapes that are repeated at different scales of size. These features are described in the patents as allowing such antennas to operate simultaneously at several frequencies, while at the same time allowing for a smaller size of antenna. Each of the four patents was asserted by Fractus against Samsung in 2013 litigation, which itself was a follow-on litigation to one that commenced in 2009 and is currently on appeal to the Federal Circuit. The 2009 litigation was started prior to enactment of the AIA.

Subsequent to filing its IPR petitions, Samsung argued to the Board that the time bar provided by 35 U.S.C. § 315(b) should not apply to its petitions for two reasons. First, each of the petitions was filed before the effective date of the AIA, and therefore the one-year time-bar did not apply. Second, even if barred by the first litigation, the petitions had been filed within one year of the second litigation. Samsung’s primary argument was that the statute’s phrase “is served” in § 315(b), being written in the present tense, precludes application of this particular AIA provision to past litigations that had been pending as of the effective date of the AIA. Samsung argued that “Congress would have used ‘was served’ if it intended complaints served before enactment of the America Invents Act also to trigger the one year deadline.”

The Board disagreed, noting the legislative history of § 315(b) clearly indicates that Congress intended IPRs to provide quick and cost-effective alternatives to litigation and that the statute was intended to set a deadline to prevent IPRs from being used as a tool for harassing patent owners by repeated litigation and administrative attacks.

The Board also noted that § 315(b) is not a statute that authorizes institution of an IPR within one-year of being served with a complaint for patent infringement, but rather one that bars institution of an IPR based on prior litigation asserting the patent in question. .

Practice Note: Because decisions by the Board not to institute an inter partes review are not appealable, (§ 314(d)), it appears that this will be the final word on the issue of time-bars based on pre-AIA litigation. The Board also made it clear that it will quickly dismiss IPR petitions filed after the one-year time-bar provided by § 315(b). Alleged infringers should docket and dutifully monitor that one-year IPR deadline. In situations where a party engaged in prior litigation may consider filing a petition for post-grant review, it should evaluate whether the asserted patent is a covered business method (CBM). Such proceedings do not have a time-bar. A time-barred defendant may also consider joining a third-party’s IPR utilizing the joinder provision of § 315(c), and complying with the relevant provisions of that statute.

Patents / Prosecution Fees

USPTO Releases New Fee Schedule *Web Only*

The U.S. Patent and Trademark Office (USPTO) released a new fee schedule effective January 1, 2014. Most of the fees remain unchanged from the March 19, 2013 fee schedule. The most significant changes are the reduction in the issue fee and the elimination of the publication fee.

According to the new fee schedule, the utility and reissue issue fees decrease from $1,780 to $960. The design issue fee is reduced from $1,020 to $560, and the plant issue fee drops from $1400 to $760. There are corresponding issue fee reductions for small and microentities.

The USPTO has eliminated the distinction between unavoidable and unintentional late payment of a maintenance fee, and now charges a large entity fee of $1,700 for a petition for the delayed payment of the fee for maintaining a patent in force. The petition fee is $850 for both small and microentities. Likewise, the USPTO has eliminated the distinction between unavoidable and unintentional abandonment, and the fee for petitioning for revival of an abandoned application is the same as the petition for delayed maintenance fee payment.

In addition, the petition fee for a delayed submission of a priority claim or to restore the benefit of priority is increased from $1420 to $1700 for a large entity. The small and microentity fee is now $850.

The USPTO also imposed minor increases in a number of Patent Cooperation Treaty (PCT) fees to foreign offices. These fees are subject to periodic increases due to fluctuations in the exchange rate.

Trademarks

Trademarks / Gray-Market Goods

No Non-Organic Mushrooms Welcome Here!

Addressing the issue of whether an importer of non-organic mushrooms from a Japanese producer infringed a trademark owned by the U.S. subsidiary of the Japanese producer, the U.S. Court of Appeals for the Ninth Circuit upheld summary judgment in favor of the U.S. subsidiary because the imported non-organic mushrooms were materially different from the U.S. grown organic mushrooms, but bore the same mark and was thus likely to cause consumer confusion. Hokto Kinoko Co. and Hokuto Co., Ltd. v. Concord Farms, Inc., Case No. 11-56461 (9th Cir., Dec. 24, 2013) (Wardlaw, J.)

Hokto USA, a wholly owned subsidiary of Hokuto Japan, cultivates U.S. certified organic mushrooms in its state-of-the-art U.S. facility. Before the facility was completed in 2009, Hokto USA imported mushrooms from Hokuto Japan which grew and packaged its mushrooms to suit U.S. consumer preferences and in growing conditions that met U.S. Certified Organic Standards (COS). The defendants’, Concord Farms imports nonorganic mushrooms from Hokuto Japan that do not satisfy the COS.

Hokto USA sued Concord Farms for trademark infringement after discovering Hokuto Japan’s Japanese-made non-organic mushrooms mixed in with Hokto USA’s U.S.-made organic mushrooms displayed side-by-side in a grocery store under a sign that said “organic” and “made in the USA.” The district court granted summary judgment and issued a permanent injunction in Hokto USA’s favor. Concord Farm appealed.

Concord Farms’ imported Hokuto Japan mushrooms were “gray-market goods” because they were legitimately produced abroad under a valid U.S. trademark. A “gray-market good” infringes a trademark if there is a likelihood of consumer confusion unless the imported goods were “genuine.” The 9th Circuit found that Concord Farms imported Hokuto Japan mushrooms that were not “genuine” Hokto USA mushrooms because of material differences in quality control, language and packaging. For example, Hokto USA mushrooms were organic, produced and packaged under controlled conditions for an American market (e.g., in English). Indeed, when it imported organic mushrooms from Hokuto Japan (before its U.S. facility was operational), Hokuto Japan used conditions that met U.S. Certified Organic Standards. Concord Farms, on the other hand, imported Hokuto Japan mushrooms produced for Japanese consumption (e.g.,in Japanese) and made under conditions that did not meet U.S. Certified Organic Standards.

After finding the Concord Farms’ mushrooms were not “genuine” Hokto USA mushrooms, the 9th Circuit analyzed infringement under the traditional Sleekcraft factors. Despite no evidence of actual confusion, the 9th Circuit found the importation of Hokuto Japan mushrooms was likely to confuse consumers into thinking they were Hokto USA mushrooms, noting that the marks were identical and strong, the two products are related, sold in similar marketing channels and in direct competition, and that mushrooms were a low-cost good commanding less scrutiny from consumers.

Finally, because Hokuto Japan and Hokto USA had a “close working relationship” to control the quality of the mushrooms distributed by the latter, the 9th Circuit was not persuaded by the argument that Hokuto Japan had issued Hokto USA a “naked license” that lacked an explicit mechanism for quality control.

Practice Note: Simply because a producer makes quality goods for one distributor does not mean it will do so for another.

Trademarks / Expenses of the Proceeding

Take Them to District Court and You’ll Have to Pay the Lawyers

Addressing for the first time whether attorneys’ fees are included in the statute, the U.S. District Court for the Eastern District of Virginia held that “all expenses of the proceedings” under 15 U.S.C.§ 1071(b)(3) includes attorneys’ fees and paralegal salaries. Shammas v. Focarino, Case No. 12-cv-1462 (E.D. Va. Jan 2, 2014) (Ellis, J.).

Section 1071(b)(3) plainly allows a party dissatisfied with a trademark decision of the Trademark Trial and Appeal Board (TTAB) to choose between an appeal at the U.S. Court of Appeals for the Federal Circuit or an action in district court. An important consideration in this decision is the fact that the statute provides that “win, lose or draw,” the party bringing an action in district court must pay the Patent and Trademark Office (PTO) “all expenses of the proceeding.” The dispute in the case centered on whether this included the PTO attorneys’ fees. The district court found that “the question is not difficult to resolve; it is a straightforward case of statutory interpretation with the analysis beginning and ending with the plain language of the statute.” The court went on to find that the standard definition of expenses “would clearly seem to include attorney’s fees.” To the extent there was any doubt, Congress’s addition of “all” to clarify “expenses” makes it “pellucidly clear Congress intended that the plaintiff in such an action pay for all the resources expended by the PTO during the litigation, including attorney’s fees.” The district court further justified its decision by examining a variety of statutes that explicitly included attorneys’ fees as a subset of expenses. Based on its conclusion that attorneys’ fees were to be included in the amount a party challenging a TTAB decision in district court must pay, the court ordered the plaintiff to reimburse the PTO $32,836.27 in attorney salary, $3,090.32 in paralegal salary and $393.90 in photocopying expenses.

Practice Note: If a party decides to challenge a TTAB decision in district court, it must be prepared to reimburse the government for the salaries of those involved in defending the PTO’s decision.

Autoren

Paul Devinsky

Counsel

Washington, DC

More Insights